KALVHealthcareSmall-Cap
KalVista Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for KalVista Pharmaceuticals, Inc. (KALV), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are KALV insiders buying or selling?
KalVista Pharmaceuticals, Inc. insiders reported 19 open-market buys ($42.6M) and 187 sells ($65.1M) across 206 Form 4 filings — a net selling position of $22.5M.
Source: SEC EDGAR Form 4
Key Statistics (as of May 29, 2026)
Total Form 4 filings
206
SEC EDGAR
Insider filers
15
Insider buys (19)
$42.6M
Insider sells (187)
$65.1M
Insider sentiment
Net sellingNet insider flow of $22.5M in net selling.
Recent KALV insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | Sale | 33.8K | $26.78 | $905.2K |
| May 27, 2026 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | Sale | 2.0K | $26.78 | $52.6K |
| May 27, 2026 | Nicole Sweeny | Chief Commercial Officer | Sale | 1.5K | $26.78 | $39.9K |
| May 27, 2026 | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale | 2.2K | $26.78 | $60.0K |
| May 26, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 10.9K | $26.78 | $292.6K |
| May 26, 2026 | Nicole Sweeny | Chief Commercial Officer | Sale | 1.9K | $26.78 | $49.8K |
| May 26, 2026 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | Sale | 2.4K | $26.78 | $63.2K |
| May 26, 2026 | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale | 2.7K | $26.78 | $71.9K |
| May 26, 2026 | Brian Piekos | Chief Financial Officer | Sale | 1.5K | $26.78 | $39.9K |
| May 19, 2026 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | Sale | 1.1K | $26.76 | $29.7K |
| May 19, 2026 | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale | 1.0K | $26.76 | $27.6K |
| May 19, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 1.1K | $26.76 | $30.2K |
| May 13, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 3.3K | $26.71 | $88.7K |
| Apr 20, 2026 | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale | 2.7K | $20.22 | $54.3K |
| Apr 20, 2026 | Nicole Sweeny | Chief Commercial Officer | Sale | 1.9K | $20.22 | $37.6K |
| Apr 20, 2026 | Brian Piekos | Chief Financial Officer | Sale | 1.9K | $20.22 | $37.6K |
| Apr 20, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 9.6K | $20.22 | $193.1K |
| Mar 27, 2026 | Bong Y Koh | 10% Owner | Sale | 214.6K | $17.20 | $3.7M |
| Mar 10, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 6.7K | $16.08 | $107.6K |
| Feb 25, 2026 | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale | 5.4K | $15.57 | $83.3K |
| Feb 25, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 10.0K | $15.57 | $156.2K |
| Feb 25, 2026 | Christopher Yea | CHIEF DEVELOPMENT OFFICER | Sale | 4.3K | $15.57 | $67.7K |
| Feb 25, 2026 | Nicole Sweeny | Chief Commercial Officer | Sale | 4.0K | $15.57 | $61.9K |
| Feb 25, 2026 | Brian Piekos | Chief Financial Officer | Sale | 1.8K | $15.57 | $27.5K |
| Feb 20, 2026 | Benjamin L Palleiko | CHIEF EXECUTIVE OFFICER | Sale | 1.0K | $15.00 | $15.6K |
Showing the 25 most recent of 206 Form 4 filings for KalVista Pharmaceuticals, Inc..
Most active KALV insiders
- Christopher Yea44 filings
- Benjamin L Palleiko38 filings
- Paul K. Audhya28 filings
- Thomas Andrew Crockett27 filings
- Edward P. Feener23 filings
Ask anything about KALV insider activity
Use Trabud's AI agent to query KalVista Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me KALV CEO purchases this year" or compare it against any other ticker.
Open the AI agentKALV insider trading FAQ
Are KalVista Pharmaceuticals, Inc. insiders buying or selling?
Across 206 SEC Form 4 filings, KalVista Pharmaceuticals, Inc. (KALV) insiders reported 19 open-market purchases totaling $42.6M and 187 sales totaling $65.1M. That is a net selling position of $22.5M.
How many insiders trade KALV stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for KalVista Pharmaceuticals, Inc.. The most recent filing was accepted on May 29, 2026.
Where does Trabud get KALV insider trading data?
All KALV insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.